Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
Launched by NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH) · Jul 21, 2001
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
The STAR\*D project will enroll 4,000 outpatients (ages 18 -75) diagnosed with nonpsychotic Major Depressive Disorder. Participants will be initially treated (open label) with citalopram, the Level 1 treatment, for a minimum of 8 weeks. Patients who experience minimal benefit will be strongly encouraged to complete 12 weeks of treatment in order to maximize the chances of symptom remission (unless no benefit at all is seen after 8 weeks). All participants will also receive a brief depression educational program.
At each level change, participants will be asked to indicate the unacceptabili...
Gender
ALL
Eligibility criteria
- • - Outpatients aged 18 to 75 years old with nonpsychotic major depressive disorder (HAMD score 14 or greater)
About National Institute Of Mental Health (Nimh)
The National Institute of Mental Health (NIMH) is a leading federal agency dedicated to advancing the understanding and treatment of mental health disorders through innovative research and clinical trials. As part of the National Institutes of Health (NIH), NIMH focuses on a broad spectrum of mental health issues, including mood disorders, anxiety disorders, schizophrenia, and developmental disorders. By fostering collaboration among researchers, clinicians, and the community, NIMH aims to translate scientific discoveries into effective interventions and improve mental health outcomes for individuals across the lifespan. Through its commitment to rigorous research methodologies and ethical standards, NIMH plays a pivotal role in shaping the future of mental health care and policy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tulsa, Oklahoma, United States
Birmingham, Alabama, United States
Tuscaloosa, Alabama, United States
Tuscaloosa, Alabama, United States
Chula Vista, California, United States
Harbor City, California, United States
Los Angeles, California, United States
Los Angeles, California, United States
San Diego, California, United States
San Diego, California, United States
Torrance, California, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Evanston, Illinois, United States
Wichita, Kansas, United States
Wichita, Kansas, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Charlestown, Massachusetts, United States
Salem, Massachusetts, United States
Ann Arbor, Michigan, United States
Ann Arbor, Michigan, United States
Glen Oaks, New York, United States
Lake Success, New York, United States
Chapel Hill, North Carolina, United States
Chapel Hill, North Carolina, United States
Chapel Hill, North Carolina, United States
Tulsa, Oklahoma, United States
Tulsa, Oklahoma, United States
Pittsburgh, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Upper St. Clair, Pennsylvania, United States
Nashville, Tennessee, United States
Nashville, Tennessee, United States
Nashville, Tennessee, United States
Nashville, Tennessee, United States
Dallas, Texas, United States
Dallas, Texas, United States
Richmond, Virginia, United States
Richmond, Virginia, United States
Patients applied
Trial Officials
A. John Rush, MD
Study Director
University of Texas Southwestern Medical Center Department of Psychiatry
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials